103 related articles for article (PubMed ID: 10594854)
21. Dysplasia arising in barrett's esophagus: diagnostic pitfalls and natural history.
Goldblum JR; Lauwers GY
Semin Diagn Pathol; 2002 Feb; 19(1):12-9. PubMed ID: 11936261
[TBL] [Abstract][Full Text] [Related]
22. Dysplasia as a predictive marker for invasive carcinoma in Barrett esophagus: a follow-up study based on 138 cases from a diagnostic variability study.
Montgomery E; Goldblum JR; Greenson JK; Haber MM; Lamps LW; Lauwers GY; Lazenby AJ; Lewin DN; Robert ME; Washington K; Zahurak ML; Hart J
Hum Pathol; 2001 Apr; 32(4):379-88. PubMed ID: 11331954
[TBL] [Abstract][Full Text] [Related]
23. Complete Barrett's eradication endoscopic mucosal resection: an effective treatment modality for high-grade dysplasia and intramucosal carcinoma--an American single-center experience.
Chennat J; Konda VJ; Ross AS; de Tejada AH; Noffsinger A; Hart J; Lin S; Ferguson MK; Posner MC; Waxman I
Am J Gastroenterol; 2009 Nov; 104(11):2684-92. PubMed ID: 19690526
[TBL] [Abstract][Full Text] [Related]
24. Nuclear accumulation of beta-catenin is a common and early event during neoplastic progression of Barrett esophagus.
Bian YS; Osterheld MC; Bosman FT; Fontolliet C; Benhattar J
Am J Clin Pathol; 2000 Oct; 114(4):583-90. PubMed ID: 11026105
[TBL] [Abstract][Full Text] [Related]
25. Expression of survivin, p53, and caspase 3 in Barrett's esophagus carcinogenesis.
Parenti A; Leo G; Porzionato A; Zaninotto G; Rosato A; Ninfo V
Hum Pathol; 2006 Jan; 37(1):16-22. PubMed ID: 16360411
[TBL] [Abstract][Full Text] [Related]
26. Epidemiology and molecular biology of Barrett esophagus.
Casson AG; Williams L; Guernsey DL
Semin Thorac Cardiovasc Surg; 2005; 17(4):284-91. PubMed ID: 16428034
[TBL] [Abstract][Full Text] [Related]
27. Survivin, a potential biomarker in the development of Barrett's adenocarcinoma.
Vallböhmer D; Peters JH; Oh D; Kuramochi H; Shimizu D; Demeester SR; Hagen JA; Chandrasoma PT; Danenberg KD; DeMeester TR; Danenberg P
Surgery; 2005 Oct; 138(4):701-6; discussion 706-7. PubMed ID: 16269299
[TBL] [Abstract][Full Text] [Related]
28. Apoptosis and cell proliferation in the metaplasia-dysplasia-carcinoma-sequence of Barrett's esophagus.
Halm U; Tannapfel A; Breitung B; Breidert M; Wittekind CW; Mössner J
Hepatogastroenterology; 2000; 47(34):962-6. PubMed ID: 11020858
[TBL] [Abstract][Full Text] [Related]
29. Low-grade dysplasia component in early invasive squamous cell carcinoma of the esophagus.
Shimizu Y; Yoshida T; Kato M; Hirota J; Ono S; Nakagawa M; Kobayashi T; Kubota K; Asaka M
J Gastroenterol Hepatol; 2010 Feb; 25(2):314-8. PubMed ID: 19968747
[TBL] [Abstract][Full Text] [Related]
30. High expression of Claudin-2 in esophageal carcinoma and precancerous lesions is significantly associated with the bile salt receptors VDR and TGR5.
Abu-Farsakh S; Wu T; Lalonde A; Sun J; Zhou Z
BMC Gastroenterol; 2017 Feb; 17(1):33. PubMed ID: 28212604
[TBL] [Abstract][Full Text] [Related]
31. The diagnosis of low-grade dysplasia in Barrett's esophagus and its implications for disease progression.
Skacel M; Petras RE; Gramlich TL; Sigel JE; Richter JE; Goldblum JR
Am J Gastroenterol; 2000 Dec; 95(12):3383-7. PubMed ID: 11151865
[TBL] [Abstract][Full Text] [Related]
32. FAP-alpha and uPA show different expression patterns in premalignant and malignant esophageal lesions.
Goscinski MA; Suo Z; Flørenes VA; Vlatkovic L; Nesland JM; Giercksky KE
Ultrastruct Pathol; 2008; 32(3):89-96. PubMed ID: 18570153
[TBL] [Abstract][Full Text] [Related]
33. Extent of low-grade dysplasia is a risk factor for the development of esophageal adenocarcinoma in Barrett's esophagus.
Srivastava A; Hornick JL; Li X; Blount PL; Sanchez CA; Cowan DS; Ayub K; Maley CC; Reid BJ; Odze RD
Am J Gastroenterol; 2007 Mar; 102(3):483-93; quiz 694. PubMed ID: 17338734
[TBL] [Abstract][Full Text] [Related]
34. Overexpression of decoy receptor 3 in precancerous lesions and adenocarcinoma of the esophagus.
Li H; Zhang L; Lou H; Ding I; Kim S; Wang L; Huang J; Di Sant'Agnese PA; Lei JY
Am J Clin Pathol; 2005 Aug; 124(2):282-7. PubMed ID: 16040301
[TBL] [Abstract][Full Text] [Related]
35. Simultaneous progression of oxidative stress and angiogenesis in malignant transformation of Barrett esophagus.
Sihvo EI; Ruohtula T; Auvinen MI; Koivistoinen A; Harjula AL; Salo JA
J Thorac Cardiovasc Surg; 2003 Dec; 126(6):1952-7. PubMed ID: 14688711
[TBL] [Abstract][Full Text] [Related]
36. p53 protein overexpression in low grade dysplasia (LGD) in Barrett's esophagus: immunohistochemical marker predictive of progression.
Weston AP; Banerjee SK; Sharma P; Tran TM; Richards R; Cherian R
Am J Gastroenterol; 2001 May; 96(5):1355-62. PubMed ID: 11374668
[TBL] [Abstract][Full Text] [Related]
37. Histopathologic evaluation of an animal model for Barrett's esophagus and adenocarcinoma of the distal esophagus.
Buskens CJ; Hulscher JB; van Gulik TM; Ten Kate FJ; van Lanschot JJ
J Surg Res; 2006 Oct; 135(2):337-44. PubMed ID: 16926029
[TBL] [Abstract][Full Text] [Related]
38. Esophageal polypoid dysplasia of gastric foveolar phenotype with focal intramucosal carcinoma associated with Barrett's esophagus.
Asthana N; Mandich D; Ligato S
Am J Surg Pathol; 2008 Oct; 32(10):1581-5. PubMed ID: 18724240
[TBL] [Abstract][Full Text] [Related]
39. Cyclooxygenase-2 expression in the Barrett's metaplasia-dysplasia-adenocarcinoma sequence.
Morris CD; Armstrong GR; Bigley G; Green H; Attwood SE
Am J Gastroenterol; 2001 Apr; 96(4):990-6. PubMed ID: 11316217
[TBL] [Abstract][Full Text] [Related]
40. Vitamin D receptor is highly expressed in precancerous lesions and esophageal adenocarcinoma with significant sex difference.
Zhou Z; Xia Y; Bandla S; Zakharov V; Wu S; Peters J; Godfrey TE; Sun J
Hum Pathol; 2014 Aug; 45(8):1744-51. PubMed ID: 24951052
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
